Wednesday 30 September 2020
Home      All news      Contact us      RSS      India
orissadiary.com - 2 month ago

Glenmark introduces higher strength (400 mg) of FabiFlu® to reduce pill burden of COVID-19 treatment

New Delhi: Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced that it will introduce a 400 mg version of oral antiviral FabiFlu®, for the treatment of mild to moderate COVID-19 in India. The higher strength will improve patient compliance and experience, by effectively reducing the number of tablets that patients require per day. [ ] The post Glenmark introduces higher strength (400 mg) of FabiFlu® to reduce pill burden of COVID-19 treatment appeared first on Odisha Breaking News | Odisha News | Latest Odisha News| Odisha Diary.


Latest News
Hashtags:   

Glenmark

 | 

introduces

 | 

higher

 | 

strength

 | 

FabiFlu®

 | 

reduce

 | 

burden

 | 

COVID

 | 

treatment

 | 

Sources